12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RK-023: Phase I started

R-Tech began a double-blind, placebo-controlled, Japanese and U.K. Phase I trial to evaluate twice-daily RK-023 applied to...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >